Klein, MD FACA FACPM Sep 23, 2025 12 min read Audience: patients and families curious about whether GLP-1based medicines (e.g., semaglutide, tirzepatide, liraglutide) might help protect brain healthespecially given growing discussion of Alzheimers disease as type 3 diabetes. The takeaway up front As a physician, I see two parallel truths emerging from recent science
The article explains that semaglutide activates GLP-1 receptors in the chemoreceptor trigger zone, a brain area sensitive to gastrointestinal signals, at the same time it slows gastric emptying and signals satiety
Sharon, Kelly Osbourne React to Hollywood Ozempic Craze Sharon Obsourne is offering insight into her weight loss journey
The outer zone is everything else: your countertop, the air, nearby objects
Most patients regain significant weight within 1 year of stopping without behavioral support (STEP 1 extension data)